– USA, MA – Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced the appointment of Joanne T. Beck, Ph.D., to its Board of Directors.
Dr. Beck has more than 25 years of pharmaceutical development and operations experience and is currently the Executive Vice President, Global Pharmaceutical Development and Operations at Celgene. She has joined the Board as Michael Ross, co-Chairman, steps down from Catabasis’ Board of Directors.
“Joanne brings deep knowledge of pharmaceutical development and operations to Catabasis, and we are excited to have her join our board of directors,” said Ken Bate, Chairman of Catabasis’ Board of Directors. “Her leadership experience and knowledge of rare disease pharmaceutical development is a significant asset to the organization as we continue NDA-enabling activities and begin initial preparations for the potential commercial launch of edasalonexent following the completion of the current Phase 3 trial in Duchenne muscular dystrophy. On behalf of the Board and the executive team at Catabasis, I also want to extend my gratitude to Mike Ross for his tremendous leadership and contributions over the past eight years. He has played a critical role in the development of Catabasis and in support of our mission.”
About Dr Joanne Beck
Dr. Beck currently serves on the Board of Directors of Orchard Therapeutics and the Alliance for Regenerative Medicine. Prior to Celgene, Dr. Beck was at Shire and served as Senior Vice President, Pharmaceutical Development from 2014 to 2016 as well as Vice President, Process Development and Manufacturing Sciences from 2012 to 2014. Dr. Beck holds a Bachelor of Arts from Lewis and Clark College (Portland, OR), a Ph.D. in Biochemistry and Molecular Biology from Oregon Health and Science University (Portland, OR) and completed a postdoctoral fellowship in the department of Pharmaceutical Chemistry at the University of California, San Francisco.
“I am thrilled to have the opportunity to support Catabasis as the organization prepares to bring forward a potential new therapy that could benefit all affected by Duchenne,” said Dr. Beck. “I see great potential for edasalonexent to change the treatment paradigm for Duchenne, and I am honored to be part of this organization and its relentless commitment to improving the lives of those affected by this devastating disease.”
At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our lead program is edasalonexent, an NF-kB inhibitor in development for the treatment of Duchenne muscular dystrophy. Our global Phase 3 PolarisDMD trial is currently enrolling boys affected by Duchenne.
For more information : https://www.catabasis.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.